DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...
In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...
Acellular tissue-engineered vessel is approved for use in adults as a vascular conduit for extremity arterial injury. (HealthDay News) — The US Food and Drug Administration has approved Symvess, the ...
Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial injuries ...
Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by ...
Removing part or all of the breast during breast cancer treatment is a potential outcome for some people. Reconstructive ...
News-Medical.Net on MSN
Injectable paste from human skin cells may improve breast reconstruction
Removing part or all of the breast during breast cancer treatment is a potential outcome for some people. Reconstructive surgical procedures often involve prosthetic implants or transplanted tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback